Maelstrom Research Staging | VISID_Vaccine_naive_subgroupB_Follow

VISID_Vaccine_naive_subgroupB_Follow_up1

Networks -

Variables -

Associated study VISID Contingency Table

Population

VISID - Vaccine naive subgroup B

The population is composed of patients who are 12 years old and older, are vaccine naive and have a combined B- and T-cell defect (Combined B-cell and T-cell immunodeficiency diagnosis).

Selection Criteria

Minimum age

Newborns

Twins

Countries

Canada

Territory

Ethnic Origin

Health Status

Other Criteria

Inclusion: Able to provide informed consent, able to speak either English or French, available for ongoing follow-up as required.
Exclusion: Subclass deficiency or isolated IgA deficiency without confirmatory testing for poor polysaccharide vaccine response, recent (<6 months) or concomitant use of other immunosuppressive agents (only for subgroup AII), evidence of HIV infection, contraindicated from receiving COVID-19 vaccines.

Recruitment

Sources of recruitment

Specific population

Specific Population

Clinic patients

Supplementary Information

Potential participants were recruited from many sources, including specialty clinics for Immunology, Malignant Hematology, Neurology and Rheumatology as well as Medical Day Units and Public Health Immunization Clinics across Canada.

Number of Participants

Number of Participants: 33
Number of Participants with Biological Samples: 33

More info

Data Collection Event

VISID - Vaccine naive subgroup B - Follow-up 1

Information was collected about medical history, concomitant medications, vaccine administration and adverse events. A blood sample was collected.

More info

Collected Dataset / VISID_Vaccine_naive_subgroupB_Follow_up1

VISID_Vaccine_naive_subgroupB_Follow_up1

Population

VISID - Vaccine naive subgroup B

Data Collection Event

VISID - Vaccine naive subgroup B - Follow-up 1

Files

Variables Classifications